Randomized clinical trial of lovastatin in HIV-infected, HAART naïve patients (NCT00721305) - 11/11/12
, Edwin A. Higuita a, Santiago Estrada b, Francisco J. Gutierrez c, Pedro Amariles d, Newar A. Giraldo e, Margarita M. Jimenez f, Claudia P. Velasquez g, Alba L. Leon h, Maria T. Rugeles a, Fabian A. Jaimes h
Corresponding author. Immunovirology Group, University of Antioquia, Calle 62, No 52–59, Torre 2, Lab 532, Medellin, Colombia. Tel.: +57 4 219 64 84; fax: +57 4 219 64 82.Summary |
Background |
Evidence suggests that statins may modify the immune response against HIV. The aim was to evaluate the antiretroviral and immunomodulatory effects of lovastatin in HIV-infected patients, naïve for antiretroviral therapy.
Methods |
Randomized, double-blinded, placebo-controlled, phase-II clinical trial. Primary outcomes were plasma viral load and circulating CD4+ T cell count, after 6 and 12 months of treatment; secondary outcomes were CD8+ T cell count, expression of activation markers (CD38 and HLA-DR) on T cells, and clinical outcomes. With a power of 90% to detect both a decrease of 0.3 log10 in plasma HIV-1 RNA copies and an increase of 20% in the CD4+ T cell count, we estimated a required sample size of 110 HIV-infected patients (55 per group). The results were analyzed by a model of repeated measurements using Generalized Estimating Equations.
Results |
Patients were randomized to receive either lovastatin (n = 55) or placebo (n = 57). During the 12-month follow-up, there was no effect of lovastatin either on viral load (estimated average change = 0.157 copies/mL; CI 95% = −0.099 to 0.414), or on the CD4+ T cell count (estimated average change = −26.1 cells/μL; CI 95% = −89.8 to 37.6). Moreover, there were no significant differences in secondary outcomes.
Conclusions |
Daily administration of lovastatin (40 mg) for one year in HIV-infected patients, naïve for antiretroviral therapy, had no significant effect on HIV replication, the CD4+ T cell count, or the activation level of T cells.
(www.clinicaltrials.gov; ID NCT00721305).
Le texte complet de cet article est disponible en PDF.Keywords : HIV infection, Anti-HIV agents, Statin, Lovastatin, Randomized controlled trial
Plan
Vol 65 - N° 6
P. 549-558 - décembre 2012 Retour au numéro
Article précédent
- Multiplex PCR of sonication fluid accurately differentiates between prosthetic joint infection and aseptic failure
- María Eugenia Portillo, Margarita Salvadó, Lluisa Sorli, Albert Alier, Santos Martínez, Andrej Trampuz, Julià Gómez, Lluis Puig, Juan Pablo Horcajada
- Seven-year surveillance of nosocomial invasive aspergillosis in a French University Hospital
- Cécile Garnaud, Marie-Pierre Brenier-Pinchart, Anne Thiebaut-Bertrand, Rebecca Hamidfar, Jean-Louis Quesada, Annick Bosseray, Bernadette Lebeau, Marie-Reine Mallaret, Danièle Maubon, Christel Saint-Raymond, Claudine Pinel, Virginie Hincky, Dominique Plantaz, Muriel Cornet, Hervé Pelloux
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?